Give full play to the clinical application value of laser photocoagulation to improve the treatment of ocular fundus diseases_Chinese Journal of Ocular Fundus Diseases

Authors：

 Jin Chenjin , Zhou Lijun

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou 510060, China;

Corresponding author：

Jin Chenjin, Email: jinchj@mail.sysu.edu.cn

Keywords：

Laser coagulation; Retinal diseases; Editorial

DOI：

10.3760/cma.j.cn511434-20210813-00436

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Laser photocoagulation has played an important role in the treatment of fundus diseases. Although anti-vascular endothelial growth factor drugs have been widely used in recent years and have gradually become the main therapy for some diseases, it still cannot substitute laser photocoagulation. A combination of anti-vascular endothelial growth factor and laser photocoagulation may optimize the treatment management and improve efficacy. With the development of technology, new laser equipment will certainly continue to appear and move towards minimally invasive automation and intellgentialization. Therefore, it is necessary for us to understand the current situation and trend of laser therapy in order to serve our patients better.

Citation： Jin Chenjin, Zhou Lijun. Give full play to the clinical application value of laser photocoagulation to improve the treatment of ocular fundus diseases. Chinese Journal of Ocular Fundus Diseases, 2021, 37(8): 585-588. doi: 10.3760/cma.j.cn511434-20210813-00436 Copy

1.	The Diabetic Retinopathy Study Research Group. Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14[J]. Int Ophthalmol Clin, 1987, 27(4): 239-253. DOI: 10.1097/00004397-198702740-00004.
2.	Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9[J]. Ophthalmology, 1991, 98(5 Suppl): S766-785.
3.	Gross JG, Glassman AR, Liu D, et al. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial[J]. JAMA Ophthalmol, 2018, 136(10): 1138-1148. DOI: 10.1001/jamaophthalmol.2018.3255.
4.	Dorin G. Subthreshold and micropulse diode laser photocoagulation[J]. Semin Ophthalmol, 2003, 18(3): 147-153. DOI: 10.1076/soph.18.3.147.29812.
5.	Scholz P, Altay L, Fauser S. A review of subthreshold micropulse laser for treatment of macular disorders[J]. Adv Ther, 2017, 34(7): 1528-1555. DOI: 10.1007/s12325-017-0559-y.
6.	Inagaki K, Shuo T, Katakura K, et al. Sublethal photothermal stimulation with a micropulse laser induces heat shock protein expression in ARPE-19 cells[J/OL]. J Ophthalmol, 2015, 2015: 729792[2015-11-30]. https://pubmed.ncbi.nlm.nih.gov/26697211/. DOI: 10.1155/2015/729792.
7.	Li Z, Song Y, Chen X, et al. Biological modulation of mouse RPE cells in response to subthreshold diode micropulse laser treatment[J]. Cell Biochem Biophys, 2015, 73(2): 545-552. DOI: 10.1007/s12013-015-0675-8.
8.	Zhou L, Chong V, Lai K, et al. A pilot prospective study of 577-nm yellow subthreshold micropulse laser treatment with two different power settings for acute central serous chorioretinopathy[J]. Lasers Med Sci, 2019, 34(7): 1345-1351. DOI: 10.1007/s10103-019-02721-8.
9.	Zhou L, Lai K, Jin L, et al. Subthreshold micropulse laser vs. conventional laser for central serous chorioretinopathy: a randomized controlled clinical trial[J/OL]. Front Med (Lausanne), 2021, 8: 682264[2021-07-16]. https://pubmed.ncbi.nlm.nih.gov/34336888/. DOI: 10.3389/fmed.2021.682264.
10.	Sun Z, Huang Y, Nie C, et al. Efficacy and safety of subthreshold micropulse laser compared with threshold conventional laser in central serous chorioretinopathy[J]. Eye (Lond), 2020, 34(9): 1592-1599. DOI: 10.1038/s41433-019-0692-8.
11.	van Dijk EHC, Fauser S, Breukink MB, et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial[J]. Ophthalmology, 2018, 125(10): 1547-1555. DOI: 10.1016/j.ophtha.2018.04.021.
12.	Inagaki K, Ohkoshi K, Ohde S, et al. Comparative efficacy of pure yellow (577-nm) and 810-nm subthreshold micropulse laser photocoagulation combined with yellow (561-577-nm) direct photocoagulation for diabetic macular edema[J]. Jpn J Ophthalmol, 2015, 59(1): 21-28. DOI: 10.1007/s10384-014-0361-1.
13.	Joondeph BC, Joondeph HC, Blair NP. Retinal macroaneurysms treated with the yellow dye laser[J]. Retina, 1989, 9(3): 187-192. DOI: 10.1097/00006982-198909030-00005.
14.	Citirik M. The impact of central foveal thickness on the efficacy of subthreshold micropulse yellow laser photocoagulation in diabetic macular edema[J]. Lasers Med Sci, 2019, 34(5): 907-912. DOI: 10.1007/s10103-018-2672-9.
15.	Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase Ⅲ randomized trials: RISE and RIDE[J]. Ophthalmology, 2012, 119(4): 789-801. DOI: 10.1016/j.ophtha.2011.12.039.
16.	Muqit MM, Marcellino GR, Henson DB, et al. Single-session vs multiple-session pattern scanning laser panretinal photocoagulation in proliferative diabetic retinopathy: the Manchester Pascal Study[J]. Arch Ophthalmol, 2010, 128(5): 525-533. DOI: 10.1001/archophthalmol.2010.60.
17.	Huang CX, Lai KB, Zhou LJ, et al. Long-term effects of pattern scan laser pan-retinal photocoagulation on diabetic retinopathy in Chinese patients: a retrospective study[J]. Int J Ophthalmol, 2020, 13(2): 239-245. DOI: 10.18240/ijo.2020.02.06.
18.	Muqit MM, Marcellino GR, Gray JC, et al. Pain responses of pascal 20 ms multi-spot and 100 ms single-spot panretinal photocoagulation: Manchester Pascal Study, MAPASS report 2[J]. Br J Ophthalmol, 2010, 94(11): 1493-1498. DOI: 10.1136/bjo.2009.176677.
19.	Nagpal M, Marlecha S, Nagpal K. Comparison of laser photocoagulation for diabetic retinopathy using 532-nm standard laser versus multispot pattern scan laser[J]. Retina, 2010, 30(3): 452-458. DOI: 10.1097/IAE.0b013e3181c70127.
20.	Velez-Montoya R, Guerrero-Naranjo JL, Gonzalez-Mijares CC, et al. Pattern scan laser photocoagulation: safety and complications, experience after 1301 consecutive cases[J]. Br J Ophthalmol, 2010, 94(6): 720-724. DOI: 10.1136/bjo.2009.164996.
21.	Kernt M, Cheuteu R, Vounotrypidis E, et al. Focal and panretinal photocoagulation with a navigated laser (NAVILAS®)[J/OL]. Acta Ophthalmol, 2011, 89(8): e662-e664[2010-10-14]. https://pubmed.ncbi.nlm.nih.gov/20946326/. DOI: 10.1111/j.1755-3768.2010.02017.x.
22.	Chhablani J, Mathai A, Rani P, et al. Comparison of conventional pattern and novel navigated panretinal photocoagulation in proliferative diabetic retinopathy[J]. Invest Ophthalmol Vis Sci, 2014, 55(6): 3432-3438. DOI: 10.1167/iovs.14-13936.
23.	Ober MD, Kernt M, Cortes MA, et al. Time required for navigated macular laser photocoagulation treatment with the Navilas[J]. Graefe's Arch Clin Exp Ophthalmol, 2013, 251(4): 1049-1053. DOI: 10.1007/s00417-012-2119-0.
24.	Chen H, Pan X, Yang J, et al. Application of 5G technology to conduct real-time teleretinal laser photocoagulation for the treatment of diabetic retinopathy[J/OL]. JAMA Ophthalmol, 2021, 2021: E1[2021-07-08]. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2781796. DOI:10.1001/jamaophthalmol.2021.2312. [published online ahead of print].
25.	Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies[J]. Ophthalmology, 2016, 123(11): 2376-2385. DOI: 10.1016/j.ophtha.2016.07.032.
26.	Flaxel CJ, Adelman RA, Bailey ST, et al. Retinal vein occlusions preferred practice pattern®[J]. Ophthalmology, 2020, 127(2): P288-P320. DOI: 10.1016/j.ophtha.2019.09.029.
27.	Callanan DG, Gupta S, Boyer DS, et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema[J]. Ophthalmology, 2013, 120(9): 1843-1851. DOI: 10.1016/j.ophtha.2013.02.018.
28.	Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema[J]. Ophthalmology, 2011, 118(4): 615-625. DOI: 10.1016/j.ophtha.2011.01.031.
29.	Schule G, Huttmann G, Framme C, et al. Noninvasive optoacoustic temperature determination at the fundus of the eye during laser irradiation[J]. J Biomed Opt, 2004, 9(1): 173-179. DOI: 10.1117/1.1627338.
30.	Vessey KA, Ho T, Jobling AI, et al. Nanosecond laser treatment for age-related macular degeneration does not induce focal vision loss or new vessel growth in the retina[J]. Invest Ophthalmol Vis Sci, 2018, 59(2): 731-745. DOI: 10.1167/iovs.17-23098.
31.	Guymer RH, Wu Z, Hodgson LAB, et al. Subthreshold nanosecond laser intervention in age-related macular degeneration: the LEAD randomized controlled clinical trial[J]. Ophthalmology, 2019, 126(6): 829-838. DOI: 10.1016/j.ophtha.2018.09.015.
32.	Xu F, Xiang Y, Wan C, et al. Predicting subretinal fluid absorption with machine learning in patients with central serous chorioretinopathy[J/OL]. Ann Transl Med, 2021, 9(3): 242[2021-02-11]. https://pubmed.ncbi.nlm.nih.gov/33708869/. DOI: 10.21037/atm-20-1519.
33.	Hanna V, Oakley J, Russakoff D, et al. Effects of subthreshold nanosecond laser therapy in age-related macular degeneration using artificial intelligence(STAR-AI Study)[J/OL]. PLoS One, 2021, 16(4): e0250609[2021-04-29]. https://pubmed.ncbi.nlm.nih.gov/33914797/. DOI: 10.1371/journal.pone.0250609.

1. The Diabetic Retinopathy Study Research Group. Indications for photocoagulation treatment of diabetic retinopathy: Diabetic Retinopathy Study Report no. 14[J]. Int Ophthalmol Clin, 1987, 27(4): 239-253. DOI: 10.1097/00004397-198702740-00004.
2. Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9[J]. Ophthalmology, 1991, 98(5 Suppl): S766-785.
3. Gross JG, Glassman AR, Liu D, et al. Five-year outcomes of panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial[J]. JAMA Ophthalmol, 2018, 136(10): 1138-1148. DOI: 10.1001/jamaophthalmol.2018.3255.
4. Dorin G. Subthreshold and micropulse diode laser photocoagulation[J]. Semin Ophthalmol, 2003, 18(3): 147-153. DOI: 10.1076/soph.18.3.147.29812.
5. Scholz P, Altay L, Fauser S. A review of subthreshold micropulse laser for treatment of macular disorders[J]. Adv Ther, 2017, 34(7): 1528-1555. DOI: 10.1007/s12325-017-0559-y.
6. Inagaki K, Shuo T, Katakura K, et al. Sublethal photothermal stimulation with a micropulse laser induces heat shock protein expression in ARPE-19 cells[J/OL]. J Ophthalmol, 2015, 2015: 729792[2015-11-30]. https://pubmed.ncbi.nlm.nih.gov/26697211/. DOI: 10.1155/2015/729792.
7. Li Z, Song Y, Chen X, et al. Biological modulation of mouse RPE cells in response to subthreshold diode micropulse laser treatment[J]. Cell Biochem Biophys, 2015, 73(2): 545-552. DOI: 10.1007/s12013-015-0675-8.
8. Zhou L, Chong V, Lai K, et al. A pilot prospective study of 577-nm yellow subthreshold micropulse laser treatment with two different power settings for acute central serous chorioretinopathy[J]. Lasers Med Sci, 2019, 34(7): 1345-1351. DOI: 10.1007/s10103-019-02721-8.
9. Zhou L, Lai K, Jin L, et al. Subthreshold micropulse laser vs. conventional laser for central serous chorioretinopathy: a randomized controlled clinical trial[J/OL]. Front Med (Lausanne), 2021, 8: 682264[2021-07-16]. https://pubmed.ncbi.nlm.nih.gov/34336888/. DOI: 10.3389/fmed.2021.682264.
10. Sun Z, Huang Y, Nie C, et al. Efficacy and safety of subthreshold micropulse laser compared with threshold conventional laser in central serous chorioretinopathy[J]. Eye (Lond), 2020, 34(9): 1592-1599. DOI: 10.1038/s41433-019-0692-8.
11. van Dijk EHC, Fauser S, Breukink MB, et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial[J]. Ophthalmology, 2018, 125(10): 1547-1555. DOI: 10.1016/j.ophtha.2018.04.021.
12. Inagaki K, Ohkoshi K, Ohde S, et al. Comparative efficacy of pure yellow (577-nm) and 810-nm subthreshold micropulse laser photocoagulation combined with yellow (561-577-nm) direct photocoagulation for diabetic macular edema[J]. Jpn J Ophthalmol, 2015, 59(1): 21-28. DOI: 10.1007/s10384-014-0361-1.
13. Joondeph BC, Joondeph HC, Blair NP. Retinal macroaneurysms treated with the yellow dye laser[J]. Retina, 1989, 9(3): 187-192. DOI: 10.1097/00006982-198909030-00005.
14. Citirik M. The impact of central foveal thickness on the efficacy of subthreshold micropulse yellow laser photocoagulation in diabetic macular edema[J]. Lasers Med Sci, 2019, 34(5): 907-912. DOI: 10.1007/s10103-018-2672-9.
15. Nguyen QD, Brown DM, Marcus DM, et al. Ranibizumab for diabetic macular edema: results from 2 phase Ⅲ randomized trials: RISE and RIDE[J]. Ophthalmology, 2012, 119(4): 789-801. DOI: 10.1016/j.ophtha.2011.12.039.
16. Muqit MM, Marcellino GR, Henson DB, et al. Single-session vs multiple-session pattern scanning laser panretinal photocoagulation in proliferative diabetic retinopathy: the Manchester Pascal Study[J]. Arch Ophthalmol, 2010, 128(5): 525-533. DOI: 10.1001/archophthalmol.2010.60.
17. Huang CX, Lai KB, Zhou LJ, et al. Long-term effects of pattern scan laser pan-retinal photocoagulation on diabetic retinopathy in Chinese patients: a retrospective study[J]. Int J Ophthalmol, 2020, 13(2): 239-245. DOI: 10.18240/ijo.2020.02.06.
18. Muqit MM, Marcellino GR, Gray JC, et al. Pain responses of pascal 20 ms multi-spot and 100 ms single-spot panretinal photocoagulation: Manchester Pascal Study, MAPASS report 2[J]. Br J Ophthalmol, 2010, 94(11): 1493-1498. DOI: 10.1136/bjo.2009.176677.
19. Nagpal M, Marlecha S, Nagpal K. Comparison of laser photocoagulation for diabetic retinopathy using 532-nm standard laser versus multispot pattern scan laser[J]. Retina, 2010, 30(3): 452-458. DOI: 10.1097/IAE.0b013e3181c70127.
20. Velez-Montoya R, Guerrero-Naranjo JL, Gonzalez-Mijares CC, et al. Pattern scan laser photocoagulation: safety and complications, experience after 1301 consecutive cases[J]. Br J Ophthalmol, 2010, 94(6): 720-724. DOI: 10.1136/bjo.2009.164996.
21. Kernt M, Cheuteu R, Vounotrypidis E, et al. Focal and panretinal photocoagulation with a navigated laser (NAVILAS®)[J/OL]. Acta Ophthalmol, 2011, 89(8): e662-e664[2010-10-14]. https://pubmed.ncbi.nlm.nih.gov/20946326/. DOI: 10.1111/j.1755-3768.2010.02017.x.
22. Chhablani J, Mathai A, Rani P, et al. Comparison of conventional pattern and novel navigated panretinal photocoagulation in proliferative diabetic retinopathy[J]. Invest Ophthalmol Vis Sci, 2014, 55(6): 3432-3438. DOI: 10.1167/iovs.14-13936.
23. Ober MD, Kernt M, Cortes MA, et al. Time required for navigated macular laser photocoagulation treatment with the Navilas[J]. Graefe's Arch Clin Exp Ophthalmol, 2013, 251(4): 1049-1053. DOI: 10.1007/s00417-012-2119-0.
24. Chen H, Pan X, Yang J, et al. Application of 5G technology to conduct real-time teleretinal laser photocoagulation for the treatment of diabetic retinopathy[J/OL]. JAMA Ophthalmol, 2021, 2021: E1[2021-07-08]. https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2781796. DOI:10.1001/jamaophthalmol.2021.2312. [published online ahead of print].
25. Heier JS, Korobelnik JF, Brown DM, et al. Intravitreal aflibercept for diabetic macular edema: 148-week results from the VISTA and VIVID studies[J]. Ophthalmology, 2016, 123(11): 2376-2385. DOI: 10.1016/j.ophtha.2016.07.032.
26. Flaxel CJ, Adelman RA, Bailey ST, et al. Retinal vein occlusions preferred practice pattern®[J]. Ophthalmology, 2020, 127(2): P288-P320. DOI: 10.1016/j.ophtha.2019.09.029.
27. Callanan DG, Gupta S, Boyer DS, et al. Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema[J]. Ophthalmology, 2013, 120(9): 1843-1851. DOI: 10.1016/j.ophtha.2013.02.018.
28. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema[J]. Ophthalmology, 2011, 118(4): 615-625. DOI: 10.1016/j.ophtha.2011.01.031.
29. Schule G, Huttmann G, Framme C, et al. Noninvasive optoacoustic temperature determination at the fundus of the eye during laser irradiation[J]. J Biomed Opt, 2004, 9(1): 173-179. DOI: 10.1117/1.1627338.
30. Vessey KA, Ho T, Jobling AI, et al. Nanosecond laser treatment for age-related macular degeneration does not induce focal vision loss or new vessel growth in the retina[J]. Invest Ophthalmol Vis Sci, 2018, 59(2): 731-745. DOI: 10.1167/iovs.17-23098.
31. Guymer RH, Wu Z, Hodgson LAB, et al. Subthreshold nanosecond laser intervention in age-related macular degeneration: the LEAD randomized controlled clinical trial[J]. Ophthalmology, 2019, 126(6): 829-838. DOI: 10.1016/j.ophtha.2018.09.015.
32. Xu F, Xiang Y, Wan C, et al. Predicting subretinal fluid absorption with machine learning in patients with central serous chorioretinopathy[J/OL]. Ann Transl Med, 2021, 9(3): 242[2021-02-11]. https://pubmed.ncbi.nlm.nih.gov/33708869/. DOI: 10.21037/atm-20-1519.
33. Hanna V, Oakley J, Russakoff D, et al. Effects of subthreshold nanosecond laser therapy in age-related macular degeneration using artificial intelligence(STAR-AI Study)[J/OL]. PLoS One, 2021, 16(4): e0250609[2021-04-29]. https://pubmed.ncbi.nlm.nih.gov/33914797/. DOI: 10.1371/journal.pone.0250609.

Next Article
Ultra-widefield imaging evaluating the efficacy of yttrium aluminum garnet laser treatment for symptomatic Weiss ring

Chinese Journal of Ocular Fundus Diseases

Give full play to the clinical application value of laser photocoagulation to improve the treatment of ocular fundus diseases

Abstract Full text Figures/Tables Video References Cited by

Next Article

Format

Content